UKPDS 39 trial
Last reviewed 01/2018
The UKPDS 39 trial aimed to determine whether a beta-blocker or an angiotensin converting enzyme inhibitor had a specific advantage or disadvantage in the prevention of macrovascular and microvascular complications of type 2 diabetes.
The trial randomly assigned patients to tight control of blood pressure (aim <150/85 mmHg) with captopril or atenolol.
Reference:
- 1) UK Prospective Diabetes Study Group (1998). Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complication in type 2 diabetes: UKPDS 39. BMJ, 317, 713-720.